# Aram Hong

> Aram Hong is the CEO and co-founder of Apollon, a Seoul-born, Cambridge-based medtech company building MOGLU, a needle-free continuous glucose monitor powered by Raman spectroscopy. A former EY advisor and Genoplan executive who moved his family from Seoul to Boston to scale the company alongside MIT researchers, Hong has turned a laser-and-optics idea into a CES 2025 Innovation Award honoree that, in peer-reviewed clinical testing, matched the accuracy of leading needle-based sensors from Abbott and Dexcom.

- **Role:** CEO and Co-founder at Apollon
- **Organizations:** Apollon, Genoplan, EY (Ernst & Young)
- **Nationality:** South Korean
- **Education:** Master of Public Policy (MPP), Georgetown University
- **Known for:** Co-founded and leads Apollon, developer of the MOGLU needle-free continuous glucose monitor, Secured a rare joint research agreement between a Korean startup and MIT's Laser Biomedical Research Center, MOGLU named a CES 2025 Innovation Awards honoree - one of only three CGM makers recognized alongside Abbott and Dexcom

## Career timeline

- **—** — Manager, Advisory at EY, focused on managing non-financial risks
- **—** — Chief Business Officer, Executive Vice President, and Board Director at Genoplan, a biotech/IT consumer genomics company
- **2021** — Co-founded Apollon to build needle-free continuous glucose monitoring using Raman spectroscopy
- **2023** — Signed a joint research collaboration with MIT's Laser Biomedical Research Center; established a U.S. subsidiary in Cambridge, Massachusetts
- **2024** — Named a CES 2025 Innovation Awards honoree for MOGLU in the Digital Health category
- **2025** — Unveiled MOGLU at CES 2025; published peer-reviewed clinical results showing accuracy comparable to Abbott and Dexcom CGMs
- **2026** — Planning clinical feasibility studies (Boston Medical Center; Joslin Diabetes Center) toward FDA submission

## Achievements

- Co-founded and leads Apollon, developer of the MOGLU needle-free continuous glucose monitor
- Secured a rare joint research agreement between a Korean startup and MIT's Laser Biomedical Research Center
- MOGLU named a CES 2025 Innovation Awards honoree - one of only three CGM makers recognized alongside Abbott and Dexcom
- Apollon holds 30+ filed and registered patents in South Korea and the U.S.
- Raised roughly $1.9M in seed funding (TIPS program selection, LG Open Innovation Grand Prize, Minister of SMEs and Startups Award)
- Co-authored peer-reviewed research showing a compact band-pass Raman CGM achieving accuracy statistically comparable to leading needle-based sensors

## Latest updates

- **2026-06** — Peer-reviewed clinical results published in the Journal of Diabetes Science and Technology; clinical feasibility study planned at Boston Medical Center in H2 2026.
- **2025-01** — Unveiled MOGLU at CES 2025 after being named a CES 2025 Innovation Awards honoree.

## Links

- Website: https://apollon.bio
- LinkedIn: https://www.linkedin.com/in/aram-hong/

---

Profile page: https://yespress.io/aram-hong
Published by YesPress — https://yespress.io
Last updated: 2026-06-25